Seat­tle and Dai­ichi Sankyo at each oth­er's throats; UC Berke­ley, UCSF and the Uni­ver­si­ty of Wash­ing­ton launch Weill Neu­ro­hub

Seat­tle Ge­net­ics and Dai­ichi Sankyo — once part­ners — are now bit­ter foes bat­tling over in­tel­lec­tu­al prop­er­ty un­der­pin­ning ADC tech­nol­o­gy. Af­ter go­ing their sep­a­rate ways, ear­li­er this year Dai­ichi en­tered in­to a mul­ti-bil­lion dol­lar pact with As­traZeneca, which gave the British drug­mak­er the li­cense to a HER2 an­ti­body de­vel­oped for use in gas­tric and breast can­cers. Seat­tle Ge­net­ics has claimed that the drug in ques­tion has been en­gi­neered us­ing an im­proved ver­sion of its tech­nol­o­gy, while Dai­ichi has cat­e­gor­i­cal­ly de­nied that claim, say­ing the drug has lit­tle to do with tech they worked on as part­ners. The two sides were locked in dis­pute res­o­lu­tion pro­ceed­ings with­out the in­volve­ment of the courts, but Dai­ichi filed a law­suit last week al­leg­ing that Seat­tle had made a “mer­it­less” claim to the in­tel­lec­tu­al prop­er­ty. On Tues­day, Seat­tle said it had re­tal­i­at­ed with an ar­bi­tra­tion de­mand to the Amer­i­can Ar­bi­tra­tion As­so­ci­a­tion to re­solve the sit­u­a­tion.

→ A $106 mil­lion gift from the Weill Fam­i­ly Foun­da­tion has helped kick start the Weill Neu­ro­hub — a re­search net­work be­tween neu­ro­sci­en­tists and re­searchers work­ing in dis­ci­plines in­clud­ing en­gi­neer­ing, com­put­er sci­ence, physics, chem­istry and math­e­mat­ics. The net­work was launched by the col­lab­o­ra­tive ef­forts of UC Berke­ley, UC San Fran­cis­co and the Uni­ver­si­ty of Wash­ing­ton. The goal of the col­lab­o­ra­tion is to speed up the de­vel­op­ment of new ther­a­pies for dis­eases and dis­or­ders that af­fect the brain and ner­vous sys­tem.

Aque­s­tive Ther­a­peu­tics, whose film ver­sion of the ALS drug rilu­zole is un­der FDA re­view, said it was hand­ing Ital­ian phar­ma­ceu­ti­cal com­pa­ny, Zam­bon, the EU rights to the prod­uct. The fi­nan­cial terms of the deal were not dis­closed.

→ Rare dis­ease-fo­cused da­ta min­ing com­pa­ny Cen­to­gene has signed a col­lab­o­ra­tion agree­ment with Pfiz­er, which grants the large US drug­mak­er ac­cess to Cen­to­gene’s da­ta repos­i­to­ry. The da­ta will be used to dis­cov­er and val­i­date ge­net­ic and bio­chem­i­cal tar­gets for the po­ten­tial de­vel­op­ment of new ther­a­pies for rare dis­eases. Fi­nan­cial de­tails re­mained un­der wraps.

→ Af­ter se­cur­ing $21.7 mil­lion in fund­ing for a Phase I/II tri­al in­volv­ing re­frac­to­ry blood can­cers and sol­id tu­mors in May, Ac­tu­ate Ther­a­peu­tics has bagged an ad­di­tion­al $6.5 mil­lion in a Se­ries B-3 fi­nanc­ing round. The round was led by Bios Part­ners, Kairos Ven­tures and DEF­TA Part­ners, along with oth­er ex­ist­ing in­vestors. This round brings the com­pa­ny’s to­tal Se­ries B fund­ing to over $28.2 mil­lion. The fund­ing will be used to­ward ini­ti­at­ing a Phase II clin­i­cal tri­al in myelofi­bro­sis ex­pand­ing an on­go­ing tri­al to in­clude an arm test­ing a com­bi­na­tion of 9-ING-41 with irinote­can.

→ Stone Cap­i­tal and Biosyn­gen have teamed up to cre­ate a Bio­phar­ma­ceu­ti­cal In­vest­ment Fund in Sin­ga­pore. The $50 mil­lion raised will be ded­i­cat­ed to in­vest­ment tar­gets for Biosyn­gen’s bio­phar­ma­ceu­ti­cal tech­nol­o­gy trans­fer plat­form and to in­cu­bate com­pa­nies.

→ Health di­ag­nos­tics com­pa­ny Sera Prog­nos­tics — fo­cused on in­di­vid­u­al­ized pre­na­tal care — has snagged $36 mil­lion in a Se­ries D fi­nanc­ing round. The round was led by Blue Ox Health­care Part­ners along with two oth­er health­care com­pa­nies. Ex­ist­ing in­vestors Do­main As­so­ci­ates, In­ter­West Part­ners, Lab­o­ra­to­ry Cor­po­ra­tion of Amer­i­ca Hold­ings, Cat­a­lyst Health Ven­tures and Chione al­so par­tic­i­pat­ed.

→ The Eu­ro­pean Com­mis­sion has grant­ed or­phan drug des­ig­na­tion to Life­Max Lab­o­ra­to­riesLM-030, an in­ves­ti­ga­tion­al ther­a­py li­censed from No­var­tis and ready to en­ter a piv­otal clin­i­cal tri­al for the treat­ment of Nether­ton syn­drome. The drug has al­ready re­ceived or­phan drug des­ig­na­tion from the FDA in June, along with rare pe­di­atric dis­ease des­ig­na­tion in Ju­ly.

Paul Hudson, Getty Images

Sanofi CEO Hud­son lays out new R&D fo­cus — chop­ping di­a­betes, car­dio and slash­ing $2B-plus costs in sur­gi­cal dis­sec­tion

Earlier on Monday, new Sanofi CEO Paul Hudson baited the hook on his upcoming strategy presentation Tuesday with a tell-tale deal to buy Synthorx for $2.5 billion. That fits squarely with hints that he’s pointing the company to a bigger future in oncology, which also squares with a major industry tilt.

In a big reveal later in the day, though, Hudson offered a slate of stunners on his plans to surgically dissect and reassemble the portfoloio, saying that the company is dropping cardio and diabetes research — which covers two of its biggest franchise arenas. Sanofi missed the boat on developing new diabetes drugs, and now it’s pulling out entirely. As part of the pullback, it’s dropping efpeglenatide, their once-weekly GLP-1 injection for diabetes.

“To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history,” Hudson said on a call with reporters, according to the Wall Street Journal. “As tough a choice as that is, we’re making that choice.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

Amarin CEO John Thero discussing the company's plans for Vascepa, August 2019 — via Bloomberg

Amarin wins a block­buster ap­proval from the FDA. Now every­one can shift fo­cus to the patent

For all those people who could never quite believe that Amarin $AMRN would get an expanded label with blockbuster implications, the stress and anxiety on display right up to the last minute on Twitter can now end. But new, pressing questions will immediately surface now that the OK has come through.

On Friday afternoon, the FDA stamped its landmark approval on the industrial strength fish oil for reducing cardio risks for a large and well defined population of patients. The approval doesn’t give Amarin everything it wants in expanding its use, losing out on the primary prevention group, but it goes a long way to doing what the company needed to make a major splash. The approval was cited for patients with “elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

Sarep­ta was stunned by the re­jec­tion of Vyondys 53. Now it's stun­ning every­one with a sur­prise ac­cel­er­at­ed ap­proval

Sarepta has a friend in the FDA after all. Four months after the agency determined that it would be wrong to give Sarepta an accelerated approval for their Duchenne MD drug golodirsen, regulators have executed a stunning about face and offered the biotech a quick green light in any case.

It was the agency that first put out the news late Thursday, announcing that Duchenne MD patients with a mutation amenable to exon 53 skipping will now have their first targeted treatment: Vyondys 53, or golodirsen. Having secured the OK via a dispute resolution mechanism, the biotech said the new drug has been priced on par with their only other marketed drug, Exondys 51 — which for an average patient costs about $300,000 per year, but since pricing is based on weight, that sticker price can even cross $1 million.

Sarepta shares $SRPT surged 23% after-market to $124.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

Paul Biondi (File photo)

Paul Biondi's track record at Bris­tol-My­ers cov­ered bil­lions in deals of every shape and size. Here's the com­plete break­down

Paul Biondi was never afraid to bet big during his stint as business development chief at Bristol-Myers Squibb. And while the gambles didn’t all pay out, by any means, his roster of pacts illustrates the broad ambitions the pharma giant has had over the last 5 years — capped by the $74 billion Celgene buyout.

On Thursday, we learned that Biondi had exited the company. And Chris Dokomajilar at DealForma came up with the complete breakdown on every buyout, licensing pact and product purchase Bristol-Myers forged during his tenure in charge of the BD team at one of the busiest companies in biopharma.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Paul Biondi (File photo)

Bris­tol-My­er­s' strat­e­gy, BD chief Paul Bion­di ex­it­ed the com­pa­ny — just ahead of the $74B Cel­gene deal close

Paul Biondi, who orchestrated billions of dollars in deals for Bristol-Myers Squibb over the 5 years he’s run their business development team, has exited the company. Biondi left last month, according to a company spokesperson, in pursuit of another — unspecified — external opportunity.

After 17 years with Bristol-Myers Squibb, Paul Biondi, Head of Strategy and Business Development, decided to leave the company to pursue an external opportunity. The company wishes him well in his new endeavors. Bristol-Myers Squibb  is actively searching for Paul’s successor, and will make an announcement, as appropriate.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

Arie Belldegrun at UKBIO 2019. Shai Dolev for Endpoints News

Kite Phar­ma's ex-CEO con­tra­dicts founder as CAR-T patent tri­al heats up, with con­flict­ing val­u­a­tions

Two days after Kite Pharma founder Arie Belldegrun told a federal courtroom that a meeting he had with a Memorial Sloan Kettering executive wasn’t about licensing their immunotherapy patent, Kite’s ex-CEO Aya Jakobovits said it was.

The admission came Tuesday during cross-examination in a patent infringement case that features two of the biggest cancer biotechs and some of the most well-known names in American medicine.

Jakobovits initially said she was not in attendance, didn’t know it was going to happen and didn’t know what took place, according to Law360. But then the plaintiff’s lawyer handed her a document – whose contents were not publicly revealed – and asked again if she learned after-the-fact that the meeting involved a potential patent license.

“Yes,” Jakobovits eventually said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

On the heels of promis­ing MCL da­ta, Kite hus­tles its 2nd CAR-T to the FDA as the next big race in the field draws to the fin­ish line

Three days after Gilead’s Kite subsidiary showed off stellar data on their number 2 CAR-T KTE-X19 at ASH, the executive team has pivoted straight to the FDA with a BLA filing and a shot at a near-term approval.

In a small, 74-patient Phase II trial reported out at the beginning of the week, investigators tracked a 93% response rate with two out of three mantle cell lymphoma patients experiencing a complete response.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

What does $6.9B buy these days in on­col­o­gy R&D? As­traZeneca has a land­mark an­swer

Given the way the FDA has been whisking through new drug approvals months ahead of their PDUFA date, AstraZeneca and their partners Daiichi Sankyo may not have to wait until Q2 of next year to get a green light on trastuzumab deruxtecan (DS-8201).

The pharma giant this morning played their ace in the hole, showing off why they were willing to commit to a $6.9 billion deal — with $1.35 billion in a cash upfront — to partner on the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.

Arie Belldegrun (Photo: Jeff Rumans for Endpoints News)

Ju­ry finds Gilead li­able for $585M and big roy­al­ties in Kite CAR-T patent case

A Kite deal that’s already become a burden on Gilead’s back just got heavier as a California jury has ruled Gilead must pay Bristol-Myers Squibb and Sloan Kettering $585 million plus a 27.6% royalty for patent infringement committed by its subsidiary. The ruling is almost certain to be appealed.

Kite Pharma — founded by Arie Belldegrun, now focused on a next-gen CAR-T company — has been facing a lawsuit since the day its first CAR–T therapy won approval in October, 2017. Juno Therapeutics and Sloan Kettering filed a complaint saying Kite had copied its technology. Gilead acquired Kite in June of that year for $11.9 billion.  Juno was acquired the following year by Celgene for $9 billion, before Celgene was acquired by Bristol-Myers Squibb in 2019.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.